Neurogene (NGNE) Stock Price, News & Analysis

Company Overview

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Key Stats

• Today's Range: $15.48 to $20.93
• 50-Day Range: $15.33 to $71.53
• 52-Week Range: $12.49 to $74.49
• Volume: 1.06 million shs
• Average Volume: 162,255 shs
• Market Capitalization: $301.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $60.83
• Consensus Rating: Buy

Neurogene Stock Analysis - MarketRank™

Neurogene scored higher than 58% of companies evaluated by MarketBeat, and ranked 467th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Neurogene has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Neurogene has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Neurogene are expected to decrease in the coming year, from ($4.45) to ($4.51) per share.

Price to Book Value per Share Ratio

Neurogene has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.89% of the float of Neurogene has been sold short.

Short Interest Ratio / Days to Cover

Neurogene has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Neurogene has recently decreased by 2.18%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neurogene does not currently pay a dividend.

Dividend Growth

Neurogene does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.89% of the float of Neurogene has been sold short.

Short Interest Ratio / Days to Cover

Neurogene has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Neurogene has recently decreased by 2.18%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.22

News Sentiment

Neurogene has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 33 news articles for Neurogene this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for NGNE on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added Neurogene to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Neurogene insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.92% of the stock of Neurogene is held by insiders.

Percentage Held by Institutions

52.37% of the stock of Neurogene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NGNE Stock Analysis - Frequently Asked Questions

How have NGNE shares performed this year?

Neurogene's stock was trading at $19.38 on January 1st, 2024. Since then, NGNE stock has increased by 4.7% and is now trading at $20.30.
View the best growth stocks for 2024 here.

How were Neurogene's earnings last quarter?

Neurogene Inc. (NASDAQ:NGNE) released its quarterly earnings data on Friday, August, 9th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.02) by $0.07. The firm had revenue of $0.93 million for the quarter.

Who are Neurogene's major shareholders?

Top institutional shareholders of Neurogene include RTW Investments LP (8.74%), Redmile Group LLC (7.42%), FMR LLC (5.63%) and Janus Henderson Group PLC (5.46%).

How do I buy shares of Neurogene?

Shares of NGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Neurogene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Neurogene investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Disc Medicine (IRON).

Company Calendar

• Last Earnings: 8/09/2024
• Today: 11/23/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Confirmed): 1/01/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NGNE
• Previous Symbol: NASDAQ:NGNE
• CUSIP: N/A
• CIK: 1404644
• Web: www.neurogene.com
• Phone: (877) 237-5020
• Fax: 778-331-4486
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $60.83
• High Stock Price Target: $72.00
• Low Stock Price Target: $45.00
• Potential Upside/Downside: +199.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-36,320,000.00
• Net Margins: N/A
• Pretax Margin: -5,756.43%
• Return on Equity: -32.81%
• Return on Assets: -27.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.09
• Quick Ratio: 12.17

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.25 per share
• Price / Book: 2.19

Miscellaneous

• Outstanding Shares: 14,850,000
• Free Float: 11,705,000
• Market Cap: $301.46 million
• Optionable: Optionable
• Beta: 1.49